Small cap Rigel drops on PhIII failure for lead fostamatinibRigel Pharmaceuticals ($RIGL) fell about 35% in early trading on news that a second Phase III trial for its fostamatinib missed the primary endpoint. Already, Wall Street had reacted poorly in August to a first Phase III trial that reported barely positive data for fostamatinib in immune thrombocytopenia (ITP).
fostamatinib結(jié)構(gòu)式
fostamatinib合成路線Merck’s letermovir hits Phase III targetMerck’s ($MRK) FDA fast-trackedantiviral letermovir has hit its primary endpoint ina Phase III test as the partners look to capitalize on Chimerix’s blowup.
Letermovir結(jié)構(gòu)式
Letermovir合成路線DMC suspends Daiichi’s 'breakthrough’ PhIII Enliven trialJapanese pharma Daiichi Sankyo and drug partner Plexxikon have stopped taking on newpatients in a late-stage trial of their rare cancer candidate on the advice ofthe Data Monitoring Committee after safety concerns.
pexidartinib結(jié)構(gòu)式
pexidartinib合成路線Celgene’s big hope ozanimod lowers pMS score in long-term ulcerative colitisAfter its $7.2 billion buyout of Receptos, Celgene ($CELG) has posted some encouraging midstage data for its acquired asset ozanimod for certain forms of inflammatory bowel disease.For patients who had been treatedwith the lower dose ozanimod 0.5-mg during the double-blindportion of the study--and were then switched to the higher 1-mg dose--mean pMS score decreased from 4.5 atentry into the extension period, to 1.7 after 44 weeks.
